1. Home
  2. TYRA vs BFS Comparison

TYRA vs BFS Comparison

Compare TYRA & BFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • BFS
  • Stock Information
  • Founded
  • TYRA 2018
  • BFS 1993
  • Country
  • TYRA United States
  • BFS United States
  • Employees
  • TYRA N/A
  • BFS N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • BFS Real Estate Investment Trusts
  • Sector
  • TYRA Health Care
  • BFS Real Estate
  • Exchange
  • TYRA Nasdaq
  • BFS Nasdaq
  • Market Cap
  • TYRA 681.7M
  • BFS 770.5M
  • IPO Year
  • TYRA 2021
  • BFS 1993
  • Fundamental
  • Price
  • TYRA $15.30
  • BFS $30.32
  • Analyst Decision
  • TYRA Strong Buy
  • BFS
  • Analyst Count
  • TYRA 7
  • BFS 0
  • Target Price
  • TYRA $30.71
  • BFS N/A
  • AVG Volume (30 Days)
  • TYRA 160.3K
  • BFS 77.3K
  • Earning Date
  • TYRA 11-06-2025
  • BFS 11-06-2025
  • Dividend Yield
  • TYRA N/A
  • BFS 7.79%
  • EPS Growth
  • TYRA N/A
  • BFS N/A
  • EPS
  • TYRA N/A
  • BFS 1.32
  • Revenue
  • TYRA N/A
  • BFS $277,902,000.00
  • Revenue This Year
  • TYRA N/A
  • BFS $6.92
  • Revenue Next Year
  • TYRA N/A
  • BFS $4.90
  • P/E Ratio
  • TYRA N/A
  • BFS $22.95
  • Revenue Growth
  • TYRA N/A
  • BFS 5.23
  • 52 Week Low
  • TYRA $6.42
  • BFS $29.97
  • 52 Week High
  • TYRA $29.60
  • BFS $42.39
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 69.86
  • BFS 31.62
  • Support Level
  • TYRA $13.29
  • BFS $30.11
  • Resistance Level
  • TYRA $13.98
  • BFS $30.75
  • Average True Range (ATR)
  • TYRA 0.68
  • BFS 0.54
  • MACD
  • TYRA 0.09
  • BFS -0.08
  • Stochastic Oscillator
  • TYRA 91.65
  • BFS 8.90

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.

Share on Social Networks: